PAD is a major manifestation of arterosclerosis and cardiovascular disease. Affecting over 10 million Americans, PAD can be a significant cause of disability and premature death.

Sponsored by several major pharmaceutical companies, CPC is studying a variety of medications to prevent the complications of PAD. By evaluating new treatment options, we hope to identify ways to improve muscle metabolism, relieve disabling symptoms that accompany this disease, and improve the patients' quality of life. We are also testing new therapies to prevent heart attack, stroke and death from peripheral arterial disease.

PAD-Related Studies and Programs

CPC is on the forefront of PAD-focused clinical trials research, with programs and studies including:

• currently enrolling subjects at our clinical site for several PAD-related clinical trials.
• managing a multi-center trial (22 sites) studying the benefits of a naturally occurring compound.
• managing a multi-center trial (35 sites) studying the benefits of a new combination cholesterol treatment.
• developing a national PAD screening program to identify people with PAD.
• developing a PAD registry to track the natural history and health outcomes in persons with this disease.